Replying to @daviesbj @TrevorHuntMD
Great job of specifying “percentage point” difference. So many mess this up!
2
150
Replying to @DavidDPope @pknoepfler
Thank you for the reply, David. I watched most of the panel and the video to which you linked. Based on that video, I think those who voted in favor of adding peptides to the list were using a different standard than FDA. Not sure where the FDA standard came from in the law.
28
Seems that REGN owend 8.6% of the company when it came public, they owed $35M per project and were on the hook for half of dev costs. Interestingly no rev projections with the deal background. sec.gov/Archives/edgar/data/… sec.gov/Archives/edgar/data/…
1
65
Replying to @given2tweet
@given2tweet "imminently certainly" sounds like there is some wiggle room in their guidance. probably good for the inhibrx cvr. probably learn a lot more on their next call.
1
347
Excellent report from Furey research partners. Small cap managers are getting crushed by the outperformance in biotech where they seem to be chronically under-exposed.
1
2
452
Replying to @given2tweet
@given2tweet look at the negotiations that happened around the akero CVR. Akero wanted until Jan 2032, novo wanted Jan 2031. They split the difference at June 2031.
2
1
199
Replying to @given2tweet @ChrisDeMuthJr
Sounds good from Sanofi call this morning. Just need some longer term exposure but they are excited about the data.
1
1
222



















